Ventyx Biosciences, Inc. (VTYX)

NASDAQ: VTYX · IEX Real-Time Price · USD
26.02
-1.48 (-5.38%)
Dec 7, 2022 4:00 PM EST - Market closed
-5.38%
Market Cap 1.56B
Revenue (ttm) n/a
Net Income (ttm) -90.98M
Shares Out 51.67M
EPS (ttm) -2.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,318,976
Open 27.19
Previous Close 27.5
Day's Range 24.38 - 27.37
52-Week Range 9.5 - 41.29
Beta n/a
Analysts Buy
Price Target 52.63 (+102.3%)
Earnings Date Nov 3, 2022

About VTYX

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhi... [Read more]

Industry Biotechnology
IPO Date Oct 21, 2021
CEO Raju S. Mohan
Employees 44
Stock Exchange NASDAQ
Ticker Symbol VTYX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for VTYX stock is "Buy." The 12-month stock price forecast is 52.63, which is an increase of 102.27% from the latest price.

Price Target
$52.63
(102.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of...

The Phase 2 trial in psoriasis will explore a broad range of doses based on Phase 1 data demonstrating class-leading safety and TYK2 target coverage

6 days ago - GlobeNewsWire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

ENCINITAS, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address...

2 weeks ago - GlobeNewsWire

Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

We are on track to initiate Phase 2 trials of our allosteric TYK2 inhibitor VTX958 in psoriasis, Crohn's disease and psoriatic arthritis this quarter

1 month ago - GlobeNewsWire

Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022

ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that addres...

1 month ago - GlobeNewsWire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that addres...

1 month ago - GlobeNewsWire

Ventyx Biosciences, Inc. (VTYX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Ventyx Biosciences, Inc. (VTYX), indicating that the stock has found support. This, combined with an upward trend in earnings e...

1 month ago - Zacks Investment Research

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Vir...

2 months ago - Investors Business Daily

Why Ventyx Biosciences Zoomed Nearly 60% Higher This Week

The biotech benefits from a much larger peer's recent FDA approval.

2 months ago - The Motley Fool

Why Is Ventyx Biosciences (VTYX) Stock Up 70% Today?

Source: metamorworks / Shutterstock Ventyx Biosciences (NASDAQ: VTYX ) stock is rocketing higher on Monday after Oppenheimer analyst Jeff Jones provided an update on the shares. That update has the Oppe...

2 months ago - InvestorPlace

You can start to dip your toes into biotech here, says Jefferies' Yee

Jefferies' Michael Yee joins 'Closing Bell' to discuss biotech stocks, which were one of the worst performers in today's sell-off. With CNBC's Michael Santoli.

Other symbols: GILDIMCRVERXVRTX
3 months ago - CNBC Television

Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

VTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial

3 months ago - GlobeNewsWire

Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958

VTX958 was well-tolerated across all SAD and MAD cohorts with an excellent safety profile

3 months ago - GlobeNewsWire

Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter ...

ENCINITAS, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that addres...

3 months ago - GlobeNewsWire

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735

Excellent safety, tolerability and pharmacokinetic profile

5 months ago - GlobeNewsWire

Ventyx Biosciences to Participate in the Jefferies Healthcare Conference

ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that addres...

6 months ago - GlobeNewsWire

Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022

6 months ago - GlobeNewsWire

Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022

ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address...

7 months ago - GlobeNewsWire

Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress

Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022

8 months ago - GlobeNewsWire

Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference

ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies f...

9 months ago - GlobeNewsWire

Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update

Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets

1 year ago - GlobeNewsWire

Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to ...

ENCINITAS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients livin...

1 year ago - GlobeNewsWire

Ventyx Jumps Over 20% Today After NASDAQ Debut

Less than a year ago, Ventyx Biosciences Inc (NASDAQ: VTYX) emerged from stealth mode, then last month, it sprinted to Wall Street with a $100 million IPO ticket. This week Ventyx nabbed an upsized $152...

1 year ago - Benzinga

Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering

ENCINITAS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living wi...

1 year ago - GlobeNewsWire